Evidence map›Paper›PMID 27377013›Full record

ArticleScientific reports2016

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.

Irina V Gribkova, Elena N Lipets, Irina G Rekhtina, Alex I Bernakevich, Dorzho B Ayusheev, Ruzanna A Ovsepyan, Fazoil I Ataullakhanov, Elena I Sinauridze

Open access · goldAbstract readValidation Study
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system.Research and practice in thrombosis and haemostasis · 2020
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Irina V GribkovaNational Research Center for Hematology, Novyi Zykovskii pr., 4, Moscow, 125167, Russia.
Elena N LipetsCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Kosygina street, 4, Moscow, 119991, Russia.
Irina G RekhtinaNational Research Center for Hematology, Novyi Zykovskii pr., 4, Moscow, 125167, Russia.
Alex I BernakevichCentral Institute of Traumatology and Orthopedics named after N.N. Priorov, Priorova Str., 10, Moscow, 127299, Russia.
Dorzho B AyusheevCentral Institute of Traumatology and Orthopedics named after N.N. Priorov, Priorova Str., 10, Moscow, 127299, Russia.
Ruzanna A OvsepyanFederal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health, Samory Mashela Str., 1, Moscow, 117997, Russia.
Fazoil I AtaullakhanovCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Kosygina street, 4, Moscow, 119991, Russia.
Elena I SinauridzeCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Kosygina street, 4, Moscow, 119991, Russia.
Central Scientific Research Institute of Traumatology and Orthopedics · RUDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology · RUFederal State Institution Hematology Research Center · RUCenter for Theoretical Problems of Physicochemical Pharmacology · RUMinistry of Health of the Russian Federation · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new oral anticoagulant, dabigatran etexilate (DE, a prodrug of direct thrombin inhibitor (DTI) dabigatran), has been used clinically to prevent thrombosis. The assessment of dabigatran efficiency is necessary in some clinical cases, such as renal insufficiency, risk of bleeding, and drug interactions. However, a specific thrombin generation test (TGT) that is one of the most informative and sensitive to anticoagulant therapy (calibrated automated thrombinography (САТ)) shows a paradoxical increase of test parameters, such as endogenous thrombin potential (ETP) and peak thrombin, in patients receiving DE. The paradoxical behaviour of ETP and peak thrombin in these patients in the presence of DTIs is mostly caused by a decrease in the activity of thrombin in the α2-macroglobulin-thrombin complex that is used as a calibrator in CAT. For a correct estimation of the TGT parameters in patient's plasma containing DTIs we proposed to use our previously described alternative calibration method that is based on the measurement of the fluorescence signal of a well-known concentration of the reaction product (7-amino-4-methylcoumarin). In this study, the validity of such approach was demonstrated in an ex vivo study in patients with knee replacement and two special patients with multiple myeloma, who received DE for thrombosis prophylaxis.

Indexed as

AntithrombinsBlood Coagulation TestsDabigatranDrug MonitoringHumansThrombosisAntithrombinsDabigatran

Identifiers

PMID27377013
PMCPMC4932519
OpenAlexW2464582306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.